Edition:
United Kingdom

Pharmaceuticals

Page 1

Almirall reduces FY 2017 revenue, net sales and EBITDA growth estimates

Monday, 10 Jul 2017

July 10 (Reuters) - ALMIRALL SA ::PROVIDES UPDATE TO FY 2017 GUIDANCE THAT REDUCES INITIAL ESTIMATIONS FOR TOTAL REVENUES, NET SALES AND EBITDA GROWTH.SAYS FY 2017 GUIDANCE UPDATE TO TAKE ACCOUNT OF ADVERSE IMPACT OF RECENT MARKET DEVELOPMENTS IN US DERMATOLOGY.SEES FY 2017 EBITDA OF 140-170 MILLION EUROS.SEES LOW DOUBLE DIGIT DECLINE OF FY 2017 TOTAL REVENUE AND NET SALES VERSUS FY 2016.SAYS INVENTORY DESTOCKING, INAPPROPRIATE ADJUDICATION OF PATIENT ASSISTANCE PROGRAM AND GENERIC ACTICLATE WILL ADVERSELY IMPACT THE EARNINGS IN 2017.SAYS ITS BUSINESS IS PERFORMING IN LINE WITH EXPECTATIONS IN EUROPE AND REST OF THE WORLD.

Valeant appoints Arthur Shannon senior vice president, head of investor relations and communications

Monday, 19 Jun 2017

June 19 (Reuters) - Valeant Pharmaceuticals International Inc -:Valeant appoints Arthur J. Shannon as senior vice president, head of investor relations and communications.Valeant - with addition of Shannon, Scott Hirsch will assume role of senior vice president, chief business strategy officer.Valeant - Arthur J. Shannon joins co from Perrigo, Inc., where he served as vice president of global corporate affairs and european investor relations.

BioDelivery Sciences Q4 loss per share $0.29

Friday, 17 Mar 2017

Biodelivery Sciences International Inc : Biodelivery sciences provides corporate update and reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.29 . Q4 revenue $3.9 million versus i/b/e/s view $3.9 million . Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Biodelivery sciences international inc - intend to evaluate an array of belbuca-related business and commercial partnership opportunities . Biodelivery sciences international inc - expect approval of belbuca in canada in first half of 2017 .Biodelivery sciences international inc- had cash and cash equivalents of approximately $32.0 million at december 31, 2016..

Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln

Wednesday, 15 Feb 2017

Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.

Daiichi Sankyo to close Japan research unit Asubio Pharma

Friday, 10 Feb 2017

Daiichi Sankyo <4568.T>: Says to close Japan research unit Asubio Pharma .Says move aimed at further reorganising its research and development structure.

Yungshin Pharm. Ind. to dissolve biotechnology unit

Wednesday, 2 Nov 2016

Yungshin Pharm. Ind. <3705.TW>:Says it plans to dissolve its biotechnology subsidiary with record date of Dec. 31.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary